Erasca (ERAS) Price & Analysis

Compare

292 Followers

ERAS Stock Chart & Stats

$2.29

-$0.05(-2.00%)

At close: Jan 08 4:00 PM EST

$2.29

-$0.05(-2.00%)

Day’s Range― - ―

52-Week Range$1.01 - $3.30

Previous CloseN/A

Volume148.24K

Average Volume (3M)1.95M

Market Cap

$643.93M

Enterprise ValueN/A

Total Cash (Recent Filing)$300.66M

Total Debt (Recent Filing)$49.42M

Price to Earnings (P/E)―

Beta1.93

Next Earnings

Mar 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding283,670,140

10 Day Avg. Volume1,258,327

30 Day Avg. Volume1,954,961

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)1.39

Price to Sales (P/S)0.00

P/FCF Ratio-5.36

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$3.80

Price Target Upside65.94% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Competitive PositioningErasca is the only company developing both a pan-RAS molecular glue and a pan-KRAS small molecule in parallel, positioning it competitively in the RAS-driven tumor landscape.

Financial StabilityErasca has a healthy balance sheet with a cash runway extending beyond expected Phase 1 proof of concept data in 2026, indicating financial stability.

Intellectual PropertyThe issuance of a composition of matter patent for Erasca's lead pan-RAS program provides patent protection until at least September 2043, seen as a significant de-risking event.

Bears Say

Clinical ChallengesA significant amount of spending and time is required to evaluate combination options and earlier lines of therapy, with Erasca several years behind competitors.

Market CompetitionErasca faces an increasingly competitive market for molecular glue assets, leading to a reduction in peak market share expectations for its key assets.

Strategic PartnershipsErasca's melanoma drug naporafenib is unlikely to find a partner for development, impacting its growth potential.

Erasca News

Erasca price target raised to $6 from $4 at Stifel

Stifel raised the firm’s price target on Erasca (ERAS) to $6 from $4 and keeps a Buy rating...

5d ago

ERAS

RVMD

Erasca announces issuance of U.S. patent covering ERAS-0015

Erasca (ERAS) announced that the U.S. Patent and Trademark Office has issued Patent No. 12,458,647, titled “Macrocyclic Derivative...

6d ago

ERAS

Erasca initiated with a Buy at Stifel

Stifel analyst Laura Prendergast initiated coverage of Erasca (ERAS) with a Buy rating and $4 price target. The...

27d ago

ERAS

RVMD

Erasca, Inc. Advances with Promising Phase 1 Study on ERAS-4001

Erasca, Inc. (($ERAS)) announced an update on their ongoing clinical study. Study Overview: Erasca, Inc. is conducting a...

15d ago

ERAS

Erasca, Inc. Advances in Cancer Treatment with ERAS-0015 Study

Erasca, Inc. (($ERAS)) announced an update on their ongoing clinical study. Study Overview: Erasca, Inc. is conducting a...

15d ago

ERAS

Erasca’s SEACRAFT-2 Study: A Promising Step in Melanoma Treatment

Erasca, Inc. (($ERAS)) announced an update on their ongoing clinical study. Study Overview: Erasca, Inc. is conducting a...

15d ago

ERAS

Erasca’s Strategic Positioning and Growth Potential in the RAS Inhibitor Market: Analyst Recommends ‘Buy’ with $4 Price Target

Erasca (ERAS) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Damien Choplain. Damien Choplain has...

27d ago

ERAS

Unusually active option classes on open October 8th

Unusual total active option classes on open include: Erasca Inc (ERAS), Vizsla Silver Corp. (VZLA), Confluent (CFLT), ProShares...

1M ago

AGQ

Alphabet jumps after avoiding worst case in antitrust ruling: Morning Buzz

The S&P and Nasdaq indexes have received a lift from a landmark court ruling in Alphabet’s (GOOGL) favor....

2M ago

Erasca double downgraded to Underperform at BofA

As previously reported, BofA double downgraded Erasca (ERAS) to Underperform from Buy with a price target of $1,...

2M ago

ERAS

Erasca downgraded to Underperform from Buy at BofA

BofA downgraded Erasca (ERAS) to Underperform from Buy with a price target of $1.50, down from $4. Published...

2M ago

ERAS

Erasca downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley downgraded Erasca (ERAS) to Equal Weight from Overweight with a price target of $2, down from...

3M ago

ERAS

Cautious Outlook on Erasca Due to Strategic Shifts and Delayed Clinical Data

Morgan Stanley analyst Sean Laaman downgraded the rating on Erasca to a Hold yesterday, setting a price target...

3M ago

ERAS

Erasca’s Strategic Advancements in RAS Programs Justify Buy Rating

Analyst Andres Y. Maldonado of H.C. Wainwright reiterated a Buy rating on Erasca, with a price target of...

3M ago

ERAS

ERAS FAQ

What was Erasca’s price range in the past 12 months?

Erasca lowest stock price was $1.01 and its highest was $3.30 in the past 12 months.

What is Erasca’s market cap?

Erasca’s market cap is $643.93M.

When is Erasca’s upcoming earnings report date?

Erasca’s upcoming earnings report date is Mar 19, 2026 which is in 127 days.

How were Erasca’s earnings last quarter?

Currently, no data Available

Is Erasca overvalued?

According to Wall Street analysts Erasca’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Erasca pay dividends?

Erasca does not currently pay dividends.

What is Erasca’s EPS estimate?

Erasca’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Erasca have?

Erasca has 283,670,140 shares outstanding.

What happened to Erasca’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Erasca?

Currently, no hedge funds are holding shares in ERAS

Erasca Stock Smart Score

Underperform

Fundamentals

Return on Equity

-31.16%

Trailing 12-Months

Asset Growth

-15.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Erasca

Erasca, Inc. (ERAS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel oncology therapies. The company aims to eradicate cancer by targeting biological drivers of the disease using precision medicine approaches. Erasca is working on a pipeline of small molecule drugs designed to inhibit oncogenic signaling pathways and address unmet needs in cancer treatment.

Erasca (ERAS) Earnings & Revenues

Historic Earnings Reports

ERAS Stock 12 Month Forecast

Average Price Target

$3.80

▲(65.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","1.75":"$1.75","3.5":"$3.5","5.25":"$5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.42,2.6953846153846155,2.9707692307692306,3.246153846153846,3.5215384615384613,3.796923076923077,4.072307692307692,4.3476923076923075,4.623076923076923,4.898461538461539,5.173846153846154,5.44923076923077,5.724615384615385,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.42,2.526153846153846,2.632307692307692,2.7384615384615385,2.8446153846153845,2.9507692307692306,3.0569230769230766,3.1630769230769227,3.269230769230769,3.375384615384615,3.4815384615384612,3.5876923076923077,3.6938461538461533,{"y":3.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.42,2.310769230769231,2.2015384615384614,2.0923076923076924,1.983076923076923,1.873846153846154,1.7646153846153845,1.6553846153846155,1.546153846153846,1.436923076923077,1.3276923076923077,1.2184615384615385,1.1092307692307692,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.23,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >